ASCO 2019 | MRD assessment in CLL
Measurable residual disease is playing a larger role in treatment assessment of chronic lymphocytic leukemia (CLL). This topic is explored by Danielle Brander, MD, of the Duke University School of Medicine, Durham, NC. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
Get great new content delivered to your inboxSign up